NCT04911881View on ClinicalTrials.gov

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

IBI321

Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY